期刊文献+

丹红注射液联合氯吡格雷治疗急性心肌梗死患者的疗效观察 被引量:4

原文传递
导出
摘要 目的探讨丹红注射液联合氯吡格雷用于急性心肌梗死患者的临床疗效。方法将229例患者按随机法分为观察组114例和对照组115例。对照组给予氯吡格雷缓释片口服治疗,观察组在对照组基础上给予丹红注射液治疗。观察2组临床疗效和不良反应情况。结果观察组总有效率为90.4%高于对照组的74.8%,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论丹红注射液联合美托洛尔治疗急性心肌梗死能减少心肌梗死后心绞痛的发作,改善心脏功能,值得临床推广应用。
作者 王聪婕
出处 《临床合理用药杂志》 2015年第8期47-47,共1页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献3

二级参考文献23

  • 1朱礼真.梗死后心绞痛临床分析[J].医药世界,2009(4):34-35. 被引量:2
  • 2鲁桂春,杨少华.丹红注射液治疗不稳定型心绞痛48例疗效观察[J].实用中西医结合临床,2006,6(1):58-58. 被引量:10
  • 3中华医学会心血管病学分会.不稳定心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(1):6-6.
  • 4李伟英,沈建平.麝香保心丸在冠心病治疗中的作用机理研究[J].中国中医急诊,2011,20(1):114-115.
  • 5Troughton RW,Frampton CM,Yahdle TG. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide concent rations[J].{H}LANCET,2000,(9210):1126-1130.
  • 6Mairj,Friedc W,Thomass. Natriuretic peptides in assessment of left ventricular dysfunction[J].{H}Scandinavian Journal of Clinical and Laboratory Investigation Supplement,1999.132-142.
  • 7Mody FV,Sigh BN,Mohiuddin IH. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue:an evaluation by positron emission tomography[J].{H}American Journal of Cardiology,1998,(5A):42K-49K.
  • 8Labrou A,Giannoglou G,Zioutas D,Fragakis N. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention[J].Am J Cardiovasc Drugs,2007,(02):143-150.
  • 9Bonello L,Sbragia P,Amabile N,Com O. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention[J].{H}HEART,2007,(06):703-707.
  • 10Di Napoli P,Taccardi AA,Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy[J].{H}HEART,2005,(02):161-165.

共引文献23

同被引文献132

  • 1彭小平,陈璿瑛,李文娟,王梦洪,郑泽琪.丹红注射液对阿霉素大鼠心肌损伤的保护作用[J].中国老年学杂志,2015,35(1):129-131. 被引量:8
  • 2国家食品药品监督管理总局.国家药品不良反应监测年度报告(2013年)[EB/OL].2014-05-14.http://www.sds.gov.en/WS01/CL0078/99794.html.
  • 3国家食品药品监督管理总局.国家药品不良反应监测年度报告(2014年)[EB/OL].(2015-07-17)[2015-08-02]]http://www.cfda.gov.cn/WS01/CL0078/124407.html.
  • 4Chen J, Deng J, Zhang Y Y, et al. Lipid-lowering effects of Danhong injection on hyperlipidemia rats [ J ]. J Ethnopharmacol, 2014, 154: 437.
  • 5Wang D D, Fan G W, Wang Y F, et al. Vascular reactivityscreen of Chinese medicine Danhong injection identifies danshen- su as a NO-independent but PGl2-mediated relaxation factor[J]. J Cardiovasc Pharmacol, 2013, 62(5) : 457.
  • 6Su X M, Zhi X W, Cui T, et al. Vasorelaxant activities of Dan- hong injection and their differential effects on the rat abdominal aorta and mesenteric artery[ J]. J Cardiovasc Pharmacol, 2015, 65(1) : 62.
  • 7He Y, Wan H T, Du Y G, et al. Protective effect of Danhong in- jection on cerebral ischemia-repeffusion injury in rats [ J]. J Eth- nopharmacol, 2012, 144: 387.
  • 8Liu H T, Wang Y F, Olaleye O, et al. Characterization of in vivo antioxidant constituents and dual-standard quality assessment of Danhong injection[J~. Biomed Chromatogr, 2013, 27: 655.
  • 9Liu M Y, Pan Q, Chen Y L, et al. Administration of Danhong injection to diabetic db/db mice inhibits the development of dia- betic retinopathy and nephropathy [ J ~. Sci Rep, 2015, 5 : 11219.
  • 10龚利华.盐酸左氧氟沙星与丹红注射液配伍禁忌[J].中国误诊学杂志,2008,8(22):5309-5309. 被引量:7

引证文献4

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部